Go Pro
→ Trump Takes Emergency Action - Plus Elon Musk's New Venture (From Altimetry) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
GRI Bio, Inc. stock logo
GRI
GRI Bio
$1.70
+15.6%		$1.78
$1.36
▼
$80.36
$2.60M-1.229,799 shs259,730 shs
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
$1.88
-0.5%		$3.84
$1.43
▼
$60.44
$2.75M1.8396,450 shs17,241 shs
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
$0.05
+42.3%		$0.08
$0.03
▼
$6.66
$777K0.09212,077 shs68,655 shs
Vaccinex, Inc. stock logo
VCNX
Vaccinex
$0.99
$1.06
$0.31
▼
$1.50
$2.57M1.13,208 shs773 shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
GRI Bio, Inc. stock logo
GRI
GRI Bio
+15.65%+18.06%-2.30%-25.44%-95.18%
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
-0.53%-9.18%-48.35%-59.40%-96.87%
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
+42.29%+20.00%-34.56%-58.50%-98.40%
Vaccinex, Inc. stock logo
VCNX
Vaccinex
0.00%-13.91%-23.26%-10.00%+41.43%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
GRI Bio, Inc. stock logo
GRI
GRI Bio
$1.70
+15.6%		$1.78
$1.36
▼
$80.36
$2.60M-1.229,799 shs259,730 shs
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
$1.88
-0.5%		$3.84
$1.43
▼
$60.44
$2.75M1.8396,450 shs17,241 shs
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
$0.05
+42.3%		$0.08
$0.03
▼
$6.66
$777K0.09212,077 shs68,655 shs
Vaccinex, Inc. stock logo
VCNX
Vaccinex
$0.99
$1.06
$0.31
▼
$1.50
$2.57M1.13,208 shs773 shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
GRI Bio, Inc. stock logo
GRI
GRI Bio
+15.65%+18.06%-2.30%-25.44%-95.18%
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
-0.53%-9.18%-48.35%-59.40%-96.87%
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
+42.29%+20.00%-34.56%-58.50%-98.40%
Vaccinex, Inc. stock logo
VCNX
Vaccinex
0.00%-13.91%-23.26%-10.00%+41.43%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
GRI Bio, Inc. stock logo
GRI
GRI Bio
2.00
Hold$32.001,782.35% Upside
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
1.00
SellN/AN/A
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
1.00
SellN/AN/A
Vaccinex, Inc. stock logo
VCNX
Vaccinex
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest PRPH, NXTS, VCNX, and GRI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/17/2026
GRI Bio, Inc. stock logo
GRI
GRI Bio
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/15/2026
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
6/1/2026
GRI Bio, Inc. stock logo
GRI
GRI Bio
Ascendiant Capital Markets logo
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$40.00 ➝ $32.00
(Data available from 8/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
GRI Bio, Inc. stock logo
GRI
GRI Bio
N/AN/AN/AN/A$4.16 per shareN/A
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
N/AN/AN/AN/A$39.70 per shareN/A
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
$5.06M0.15N/AN/A$2.46 per share0.02
Vaccinex, Inc. stock logo
VCNX
Vaccinex
$388K6.63N/AN/A($2.59) per share-0.38
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
GRI Bio, Inc. stock logo
GRI
GRI Bio
-$11.96M-$74.16N/AN/AN/AN/A-199.52%-143.23%8/13/2026 (Estimated)
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
-$4M-$114.15N/AN/AN/AN/A-145.15%-111.82%N/A
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
-$53.36M-$3.13N/AN/AN/A-825.01%-482.05%-88.90%8/12/2026 (Estimated)
Vaccinex, Inc. stock logo
VCNX
Vaccinex
-$20.25M-$48.27N/AN/AN/AN/AN/A-383.58%N/A

Latest PRPH, NXTS, VCNX, and GRI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
GRI Bio, Inc. stock logo
GRI
GRI Bio
-$1.20N/AN/AN/AN/AN/A
5/13/2026Q1 2026
GRI Bio, Inc. stock logo
GRI
GRI Bio
-$1.6050-$1.61-$0.0050-$1.61N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
GRI Bio, Inc. stock logo
GRI
GRI Bio
N/AN/AN/AN/AN/A
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
N/AN/AN/AN/AN/A
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
N/AN/AN/AN/AN/A
Vaccinex, Inc. stock logo
VCNX
Vaccinex
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
GRI Bio, Inc. stock logo
GRI
GRI Bio
N/A
14.20
14.21
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
0.01
4.73
4.73
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
0.14
0.14
0.14
Vaccinex, Inc. stock logo
VCNX
Vaccinex
N/A
0.77
0.77

Institutional Ownership

CompanyInstitutional Ownership
GRI Bio, Inc. stock logo
GRI
GRI Bio
33.95%
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
61.24%
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
9.45%
Vaccinex, Inc. stock logo
VCNX
Vaccinex
50.11%

Insider Ownership

CompanyInsider Ownership
GRI Bio, Inc. stock logo
GRI
GRI Bio
8.73%
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
6.52%
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
9.60%
Vaccinex, Inc. stock logo
VCNX
Vaccinex
51.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
GRI Bio, Inc. stock logo
GRI
GRI Bio
11.77 million1.62 millionNot Optionable
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
21.45 million1.36 millionN/A
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
13015.59 million5.44 millionNo Data
Vaccinex, Inc. stock logo
VCNX
Vaccinex
402.60 million1.26 millionNo Data

Recent News About These Companies

Vaccinex (VCNX) Projected to Post Earnings on Monday
August 9 at 1:56 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30949501
Vaccinex to Report New Biomarker Data and Plans for Phase 2B Clinical Trial of Pepinemab in AD at the Alzheimer's Association International Conference in London on July 13, 2026
July 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/08/3324070/34858/en/vaccinex-to-report-new-biomarker-data-and-plans-for-phase-2b-clinical-trial-of-pepinemab-in-ad-at-the-alzheimer-s-association-international-conference-in-london-on-july-13-2026.html
Vaccinex, Inc. Reports Financial Results for Year Ended December 31, 2025
April 29, 2026  |  quiverquant.comQ
Vaccinex Reports 2025 Annual Financial Results
April 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/30/3284388/34858/en/vaccinex-reports-2025-annual-financial-results.html
Vaccinex Inc.
April 10, 2026  |  barrons.comhttps://www.barrons.com/market-data/stocks/vcnx/company-people
Vaccinex announces $60M revenue sharing agreement with PDV
December 23, 2025  |  msn.comhttps://www.msn.com/en-us/money/other/vaccinex-announces-60m-revenue-sharing-agreement-with-pdv/ar-AA1SUmDZ
Vaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer’s Disease
December 23, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/vaccinex-inc-announces-60-million-agreement-to-finance-a-phase-2b-clinical-trial-of-pepinemab-to-treat-alzheimer-s-disease-1035667359
Vaccinex, Inc. Engages in $60 Million Revenue Sharing Agreement with Pepinemab Development Venture to Advance Alzheimer’s Treatment
December 23, 2025  |  quiverquant.comQ
Vaccinex presents promising cancer treatment data at ASCO
May 29, 2025  |  uk.investing.comhttps://uk.investing.com/news/company-news/vaccinex-presents-promising-cancer-treatment-data-at-asco-93CH-4104876
Vaccinex, Inc. to Present New Data on Pepinemab's Role in Enhancing Immune Responses in Head and Neck Cancer at ASCO 2025
May 29, 2025  |  nasdaq.comhttps://www.nasdaq.com/articles/vaccinex-inc-present-new-data-pepinemabs-role-enhancing-immune-responses-head-and-neck
Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting
May 27, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/05/27/3088645/34858/en/vaccinex-to-report-promising-new-clinical-results-of-neoadjuvant-treatment-with-pepinemab-to-enhance-immunotherapy-in-patients-with-head-and-neck-cancer-at-asco-annual-meeting.html
AbTherx, Inc: AbTherx, Single Cell Technology, and Vaccinex Announce Collaboration to Tackle Challenging Antibody Drug Targets
May 13, 2025  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2025-05/65384714-abtherx-inc-abtherx-single-cell-technology-and-vaccinex-announce-collaboration-to-tackle-challenging-antibody-drug-targets-200.htm
AbTherx, Single Cell Technology, and Vaccinex Announce Collaboration to Tackle Challenging Antibody Drug Targets
May 13, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/abtherx-single-cell-technology-vaccinex-100000437.html
Vaccinex to report new clinical data on pepinemab in enhancing immunotherapy
April 22, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/vaccinex-to-report-new-clinical-data-on-pepinemab-in-enhancing-immunotherapy-1034603197
Vaccinex, Inc. Announces Promising Data on Pepinemab as Neoadjuvant Immunotherapy in Metastatic Melanoma and Head and Neck Cancer at AACR 2025
April 21, 2025  |  quiverquant.comQ
Vaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)
April 21, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/04/21/3064665/34858/en/vaccinex-to-report-promising-new-clinical-data-revealing-pepinemab-s-unique-mechanism-to-enhance-immunotherapy-at-annual-meeting-of-american-association-for-cancer-research-aacr.html
Vaccinex director resigns, no disagreement cited
March 21, 2025  |  investing.comhttps://www.investing.com/news/sec-filings/vaccinex-director-resigns-no-disagreement-cited-93CH-3937856
Vaccinex plans Nasdaq exit as Alzheimer market pressure grows
March 10, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/vaccinex-plans-nasdaq-exit-alzheimer-211545558.html
Vaccinex, Inc.: Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market
March 8, 2025  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2025-03/64767350-vaccinex-inc-vaccinex-plans-to-delist-its-common-stock-from-the-nasdaq-stock-market-399.htm
Vaccinex to delist common stock from Nasdaq
March 7, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/vaccinex-to-delist-common-stock-from-nasdaq-1034455385

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Two Very Large Crude Carriers (VLLCs) sailing side by side on open ocean waters, viewed from above.
Strait of Hormuz Tensions Spike Tanker Trade: These 2 Stocks Are Set to Benefit
By Dan Schmidt | July 19, 2026
Trading screen displaying a candlestick price chart, options calls and puts pricing table, and green call, red put buttons.
The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence
By Bridget Bennett | July 20, 2026
AMD logo on a glowing processor chip with red circuit traces, highlighting AI and data-center semiconductor demand.
AMD’s AI Bubble Could Burst Into Explosive Upside
By Thomas Hughes | July 27, 2026
A Patriot missile launcher and soldier on an airbase tarmac as an F-35 fighter jet flies overhead at sunset.
RTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade?
By Dan Schmidt | July 26, 2026
An oil pump jack and drilling rig stand on an arid plain at sunset.
Oil Prices Are Surging and These 4 Stocks Are Cashing In
By Bridget Bennett | July 27, 2026
GRI Bio stock logo

GRI Bio NASDAQ:GRI

$1.70 +0.23 (+15.65%)
Closing price 08/10/2026 04:00 PM Eastern
Extended Trading
$1.78 +0.08 (+4.65%)
As of 05:22 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

Nexentis Technologies stock logo

Nexentis Technologies NASDAQ:NXTS

$1.88 -0.01 (-0.53%)
Closing price 08/10/2026 04:00 PM Eastern
Extended Trading
$1.90 +0.02 (+1.06%)
As of 05:35 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

N2OFF, Inc., an agri-food tech company, engages in the development and sale of eco-friendly green solutions for the food industry to enhance food safety and shelf life of fresh produce. Its products are based on proprietary blend of food acids combined with various oxidizing agent-based sanitizers and low concentrated fungicides for cleaning, sanitizing, and controlling pathogens on fresh produce that are safer for human consumption and extend their shelf life by reducing their decay. The company's products include SavePROTECT or PeroStar, a processing aid for post-harvest application that is added to fruit and vegetable wash water; and SF3HS and SF3H, a post-harvest cleaning and sanitizing solution to control plant and foodborne pathogens. It also offers SpuDefender for controlling post-harvest potato sprouts; and FreshProtect to control spoilage-creating microorganisms on post-harvest citrus fruit. The company was formerly known as Save Foods, Inc. and changed its name to N2OFF, Inc. in March 2024. N2OFF, Inc. was incorporated in 2009 and is headquartered in Hod HaSharon, Israel.

ProPhase Labs stock logo

ProPhase Labs NASDAQ:PRPH

$0.05 +0.01 (+42.29%)
As of 08/10/2026 01:58 PM Eastern

ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.

Vaccinex stock logo

Vaccinex NASDAQ:VCNX

$0.99 0.00 (0.00%)
As of 08/7/2026 03:16 PM Eastern

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 study for treatment of Alzheimer's disease and has completed phase 2 study for treatment of Huntington's disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer, Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 study with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab completed phase 2 study for melanoma, and trastuzumab and DC vaccine in phase 2 study for breast cancer. The company has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. It has collaborations with Merck Sharp & Dohme; Ares Trading S.A.; The Children's Hospital of Philadelphia; Emory University; Huntington Study Group; H. Lee Moffitt Cancer Center and Research Institute, Inc; Catalent Pharma Solutions, LLC; Surface Oncology, Inc.; and Pharmaceutical and Biotech Co. The company was incorporated in 2001 and is headquartered in Rochester, New York.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas